<DOC>
	<DOCNO>NCT00390117</DOCNO>
	<brief_summary>RATIONALE : AT7519M may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose AT7519M treat patient advanced metastatic solid tumor refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>AT7519M Treating Patients With Advanced Metastatic Solid Tumors Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine recommend phase II dose AT7519M patient advance metastatic solid tumor refractory non-Hodgkin 's lymphoma . - Determine safety , tolerability , toxicity profile , dose-limiting toxicity drug patient . - Determine pharmacokinetic profile drug patient . - Correlate toxicity profile pharmacokinetics drug patient . Secondary - Assess , preliminarily , antitumor activity drug patient . OUTLINE : This open-label , dose-escalation , multicenter study . Patients receive AT7519M IV 1-3 hour day 1 , 4 , 8 , 11 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos AT7519M maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity course 1 . Once MTD determine , 8 additional patient treat MTD . Patients undergo blood collection periodically pharmacokinetic study . Patients treat MTD also undergo tumor tissue biopsy aspirate blood collection periodically additional pharmacodynamic correlative biomarker study . After completion study therapy , patient follow 4 week . Patients complete response , partial response , stable disease follow every 3 month thereafter relapse . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis 1 following : Advanced and/or metastatic solid tumor No 3 prior regimens metastatic disease Refractory nonHodgkin 's lymphoma Clinically radiologically document disease Patients whose evidence disease tumor marker elevation eligible No untreated brain meningeal metastases Patients radiologic clinical evidence stable , treated brain metastasis eligible provide asymptomatic AND requirement corticosteroid PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.25 time upper limit normal ( ULN ) OR creatinine clearance ≥ 50 mL/min Bilirubin normal ALT AST ≤ 2 time ULN ( 5 time ULN patient document liver metastasis ) Potassium normal Calcium normal Creatine kinase ( CK CPK ) ≤ 2 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No preexist cardiovascular condition and/or symptomatic cardiac dysfunction , include follow : Significant cardiac event ( include symptomatic heart failure angina ) within past 3 month cardiac disease , opinion investigator , increase risk ventricular arrhythmia Any history ventricular arrhythmia , symptomatic require treatment ( CTC grade 3 ) , include multifocal PVCs , bigeminy , trigeminy , ventricular tachycardia Uncontrolled hypertension Previous history QT prolongation medication Congenital long QT syndrome QT QTc , Bazett 's correction , unmeasurable ≥ 460 msec screen ECG LVEF &lt; 45 % MUGA patient significant cardiac history ( i.e. , myocardial infarction , severe hypertension , arrhythmia ) prior doxorubicin ( &gt; 450 mg/m² ) No active uncontrolled infection No serious illness medical condition would preclude study compliance No peripheral neuropathy &gt; grade 1 PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 21 day since prior cytotoxic chemotherapy recover ( solid tumor ) At least 21 day since prior palliative radiotherapy recover Exceptions may make lowdose , nonmyelosuppressive radiotherapy Prior hormonal , immunologic , biologic , signal transduction inhibitor therapy allow At least 14 day since prior major surgery recover ( nonhealing wound ) At least 4 week since prior steroid No concurrent medication affect QT/QTc discontinue No concurrent experimental drug anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>